Periplocymarin Suppresses Nonsmall Cell Lung Cancer Progression by Modulating MAPK14 Phosphorylation: An Integrated Multiomics and Preclinical Study
Nonsmall cell lung cancer (NSCLC) remains a leading malignancy with limited therapies, calling for natural product-derived anticancer candidates with well-defined mechanisms. In this study, Periplocymarin was identified as a selective anti-NSCLC candidate. Its antitumor activity was verified in cell proliferation, apoptosis, migration assays and patient-derived organoid models. To dissect its antitumor mechanism, we employed an integrated strategy combining transcriptome sequencing, network pharmacology, thermal proteome profiling (TPP), microscale thermophoresis (MST) and molecular simulations, and validated the involvement of p38α MAPK (MAPK14) phosphorylation via Western blot. Finally, the in vivo antitumor efficacy and safety of Periplocymarin were validated using nude mouse xenograft and patient-derived xenograft (PDX) models. Periplocymarin inhibited proliferation and migration and induced apoptosis in NSCLC cells in a concentration-dependent manner, while also suppressing Patient-Derived Organoid (PDO) growth. Integrated analyses and experimental validation indicated MAPK14 as a candidate target associated with Periplocymarin treatment. Periplocymarin reduced MAPK14 phosphorylation, and MAPK14 knockdown partially attenuated its antitumor effects. In vivo, Periplocymarin significantly suppressed tumor growth in nude mouse subcutaneous xenograft and PDX models, with decreased Ki-67 and phospho-MAPK14 levels and no evident toxicity. This study demonstrates Periplocymarin exerts anti-NSCLC activity via modulating MAPK14 phosphorylation, supporting its further development for NSCLC therapy.
Authors
- Xiao Liang (ORCID: https://orcid.org/0000-0003-0330-7027)
- Liting Lv (ORCID: https://orcid.org/0000-0002-2895-9489)
- Jiahai Shi (ORCID: https://orcid.org/0000-0002-8635-5376)
- X R Wang
- Yifei Liu (ORCID: https://orcid.org/0000-0001-8068-776X)
- Han Sun (ORCID: https://orcid.org/0000-0002-7850-9574)
- Yiyan Miao
- Zhibin Song (ORCID: https://orcid.org/0000-0002-8921-4499)
- Wang Mingwei
- Xingqin Zhou
- Xiaoting Ma
Institutions
- Xuzhou Medical College (CN)
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Jiangyin People's Hospital (CN)
- Jiangyin Traffic Planning Survey & Design Institute (China) (CN)
Publication Details
- Journal
- Journal of Proteome Research
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1021/acs.jproteome.6c00598
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Jiangsu Provincial Department of Human Resources and Social Security
- Graduate Research and Innovation Projects of Jiangsu Province